Cancer Drug Developers Cry Foul As Costs Soar In China
Sheer volume of studies and fierce competition to recruit and enroll required numbers of patients in trials, even in a populous country like China, can quickly jack up new drug development costs.
You may also be interested in...
Henlius has reshuffled its C-suite, with chairman Qiyu Chen stepping down from the role to take up a position as non-executive director and CEO Wenjie Zhang poised to step into his shoes.
Any delays caused by unpredictable regulatory reviews related to the export of genetic materials threaten to derail the inclusion of China in international clinical trials, caution two trade groups representing the pharma industry in the country.
As a part of real-world evidence, patient-reported outcomes can serve to evaluate a drug's efficacy against primary or secondary endpoints and also reflect safety and quality of life, notes a just-released draft regulation from China’s Center for Drug Evaluation.